NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi
Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of the investigational therapy Haduvio™
(nalbuphine ER) to treat serious neurologically mediated
conditions, today announced that Jennifer
Good, President and CEO, has been selected to deliver a
company presentation at 2021 BIO Digital. For 2021, the BIO
International Convention will be held virtually as BIO Digital, on
June 10 and 11 and from June 14-18.
The Company's presentation will be available to registered BIO
Digital attendees from 9am ET
June 10, until the end of the
conference on June 18.
An archived replay of the presentation will be available for 30
days following the conclusion of the conference by visiting 'News
& Events' in the 'Investors & News' section on the
Company's website at www.trevitherapeutics.com.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational therapy Haduvio to treat serious neurologically
mediated conditions. Trevi is conducting a Phase
2b/3 clinical trial of Haduvio for
the treatment of chronic pruritus associated with prurigo nodularis
(PN) and a Phase 2 trial for chronic cough in patients with
idiopathic pulmonary fibrosis (IPF). Trevi is also developing
Haduvio for the treatment of levodopa-induced dyskinesia (LID) in
patients with Parkinson's disease. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended release
formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor
agonist and µ-opioid receptor antagonist that has been approved and
marketed as an injectable for pain indications for more than 20
years in the United States and Europe. The ĸ- and
µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine's mechanism of
action may also mitigate the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is not currently classified as a controlled substance by
the DEA in the United States and by regulatory
authorities in most of Europe. Trevi intends to
propose Haduvio as the trade name for nalbuphine ER. Haduvio is an
investigational therapy that has been granted Fast Track
designation by FDA for the proposed indication of reduction of
moderate to severe pruritus in patients with prurigo nodularis. Its
safety and efficacy have not been evaluated by any regulatory
authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-2021-bio-digital-conference-301308705.html
SOURCE Trevi Therapeutics, Inc.